NASDAQ: KURAKura Oncology Inc Stock
$9.05+0.19 (+2.14%)
Updated Jun 12, 2026
KURA Price
$9.05
Fair Value Price
$15.71
Market Cap
$803.41M
52 Week Low
$5.45
52 Week High
$12.49
P/E
-2.7x
P/B
7.45x
P/S
10.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$71.64M
Earnings
-$294.57M
Gross Margin
99.6%
Operating Margin
-409.03%
Profit Margin
-411.2%
Debt to Equity
5.05
Operating Cash Flow
-$78M
Beta
1.1
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
KURA Overview
Kura Oncology, Inc., a biopharmaceutical firm in the clinical development stage, is dedicated to discovering and advancing cancer treatments within the United States. Its therapeutic portfolio primarily features small-molecule compounds engineered to combat various cancers. Among its leading drug candidates is ziftomenib, a small-molecule agent designed to disrupt the interaction of menin-Lysine K-specific Methyltransferase 2A proteins. This inhibitor is being developed for specific genetic forms of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Another prominent candidate is tipifarnib, an orally administered farnesyl transferase inhibitor currently undergoing Phase II clinical assessment for both solid tumors and blood-related conditions. The company has also established a clinical collaboration with Novartis to evaluate the combined therapeutic potential of tipifarnib and alpelisib. This joint effort targets patients with head and neck squamous cell carcinoma whose tumors exhibit HRAS overexpression or specific PIK3CA mutations or amplifications. Founded in 2014, Kura Oncology, Inc. operates from its headquarters in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine KURA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
KURA
Ranked#180 of 463
Ranked#180 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $230.56 | A | |
| $53.13 | A | |
| $15.82 | A |
Be the first to know about important KURA news, forecast changes, insider trades & much more!
KURA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how KURA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KURA ($9.05) is undervalued by 42.39% relative to our estimate of its Fair Value price of $15.71 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KURA ($9.05) is significantly undervalued by 42.39% relative to our estimate of its Fair Value price of $15.71 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KURA due diligence checks available for Premium users.
Valuation
KURA fair value
Fair Value of KURA stock based on Discounted Cash Flow (DCF)
Price
$9.05
Fair Value
$15.71
Undervalued by
42.39%
KURA ($9.05) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KURA ($9.05) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KURA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KURA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.7x
Industry
16.53x
Market
14.15x
KURA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.45x
Industry
4.85x
KURA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KURA's financial health
Profit margin
Revenue
$18.3M
Net Income
-$73.3M
Profit Margin
-401.5%
KURA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
KURA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$652.6M
Liabilities
$544.7M
Debt to equity
5.05
KURA's short-term assets ($623.78M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KURA's short-term assets ($623.78M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KURA's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
KURA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$85.9M
Investing
-$24.2M
Financing
$69.0k
KURA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KURA vs Biotech Stocks
Kura Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.